New business models and entrants are shaking up the industry.
The prescription drug industry was rocked last month, particularly as it relates to pricing, and it appears this went largely unnoticed.
A wide range of players, from Amazon to Aetna to Express Scripts, announced new business models and acquisitions that are poised to significantly lower drug prices. Combined with potential FDA action, federal, state, and grassroots-level efforts to increase drug pricing transparency could lower prices for patients. Perhaps, unwittingly, this could even result in a win for President Trump’s Drug pricing reform plans.
In this paper, you will learn:
- How current market forces are moving the industry toward price reduction
- The four market forces poised to reveal lower costs for patients
- How emerging business models are reshaping the way the industry will source, price, and deliver prescription drugs